In line with our work and that of others implicating JNK signaling in ALS MN degeneration (Bhinge et al., 2017; Wu et al., 2019), we observed that the JNK inhibitor SP600125, as well as the PKC inhibitor Enzastaurin and the BRAF inhibitor GDC-0879, all preserved MN viability and TUJ1 + neurite networks to levels comparable to those obtained with kenpaullone or MAP4K4 inhibitor 29 (Figures 5A, B). The gene discussed is MAP4K4; the disease is amyotrophic lateral sclerosis.